

# Whole-Exome Molecular Autopsy After Exertion-Related Sudden Unexplained Death in the Young

Jason H. Anderson, MD; David J. Tester, BS; Melissa L. Will, BS; Michael J. Ackerman, MD, PhD

**Background**—Targeted postmortem genetic testing of the 4 major channelopathy-susceptibility genes (*KCNQ1*, *KCNH2*, *SCN5A*, and *RYR2*) have yielded putative pathogenic mutations in  $\leq 30\%$  of autopsy-negative sudden unexplained death in the young (SUDY) cases with highest yields derived from the subset of exertion-related SUDY. Here, we evaluate the role of whole-exome sequencing in exertion-related SUDY cases.

**Methods and Results**—From 1998 to 2010, 32 cases of exertion-related SUDY were referred by Medical Examiners for a cardiac channel molecular autopsy. A mutational analysis of the major long-QT syndrome-susceptibility genes (*KCNQ1*, *KCNH2*, and *SCN5A*) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene (*RYR2*) identified a putative pathogenic mutation in 11 cases. Whole-exome sequencing was performed on the remaining 21 targeted gene-negative SUDY cases. After whole-exome sequencing, a gene-specific surveillance of all genes (N=100) implicated in sudden death was performed to identify putative pathogenic mutation(s). Three of these 21 decedents had a clinically actionable, pathogenic mutation (CALM2-F90L, CALM2-N98S, and PKP2-N634fs). Of the 18 remaining cases, 7 hosted at least 1 variant of unknown significance with a minor allele frequency  $< 1:20000$ . The overall yield of pathogenic mutations was higher among decedents aged 1 to 10 years (10/11, 91%) than those aged 11 to 19 years (4/21, 19%,  $P=0.0001$ ).

**Conclusions**—Molecular screening in this clinical scenario is appropriate with a pathogenic mutation detection rate of 44% using direct DNA sequencing followed by whole-exome sequencing. Only 5 of the 100 interrogated sudden death genes hosted actionable pathogenic mutations for more than one third of these exertion-related, autopsy-negative SUDY cases. (*Circ Cardiovasc Genet.* 2016;9:259-265. DOI: 10.1161/CIRCGENETICS.115.001370.)

**Key Words:** autopsy ■ exome ■ genetic testing ■ mutation ■ phenotype

Sudden death in children and young adults, affecting  $\approx 1000$  to 5000 individuals annually in the United States, is an uncommon but profoundly tragic event for families and physicians.<sup>1</sup> These deaths are often secondary to an underlying cardiac abnormality with exertion preceding sudden death. Maron et al<sup>2</sup> reported an analysis of the US National Registry of Sudden Death in Athletes composed of 1866 athletes and noted that death occurred in 82% of these individuals during or immediately after training/competition. Mellor et al<sup>3</sup> went on to demonstrate that male sex and age  $< 18$  years were independently associated with exercise/stress-related deaths. Exertion as an inciting event raises concerns for associated cardiomyopathy, such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy, or underlying channelopathy, including long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT).<sup>1</sup>

a morphological abnormality. However, a significant number of sudden deaths will remain unexplained with no identifiable structural abnormality, as in patients with a channelopathy or subtle phenotypic features of a cardiomyopathy. These cases have been labeled autopsy-negative sudden unexplained death (SUD). When clinical suspicion for a diagnosis of an arrhythmia syndrome is present, primarily LQTS or CPVT, guidelines, by the Heart Rhythm Society and European Heart Rhythm Association, recommend a molecular autopsy investigation of the SUD case (class II indication).<sup>4</sup>

The cardiac channelopathy-centric molecular autopsy currently uses targeted postmortem genetic testing of the 4 major channelopathy-susceptibility genes (*KCNQ1*, *KCNH2*, *SCN5A*, and *RYR2*). This process has yielded putative pathogenic mutations in  $\leq 30\%$  of SUD cases in the young (SUDY).<sup>5-11</sup> Tester et al<sup>5</sup> noted a slightly higher mutation detection yield among SUDY patients with an exertional trigger (35%) in comparison to a nonspecific trigger (27%) or death during sleep (19%), but the difference did not reach statistical significance. The downside of direct DNA sequencing is the limitation of data based on a one gene at a time

**Editorial, see p 210**

**Clinical Perspective on p 265**

A comprehensive medicolegal investigation with conventional autopsy examination may lead to identification of

Received December 23, 2015; accepted April 21, 2016.

From the Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine (J.H.A., M.J.A.), Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory (D.J.T., M.L.W., M.J.A.), and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN (M.J.A.).

**The Data Supplement is available at <http://circgenetics.ahajournals.org/lookup/suppl/doi:10.1161/CIRCGENETICS.115.001370/-DC1>.**

Correspondence to Michael J. Ackerman, MD, PhD, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905. E-mail [ackerman.michael@mayo.edu](mailto:ackerman.michael@mayo.edu)

© 2016 American Heart Association, Inc.

*Circ Cardiovasc Genet* is available at <http://circgenetics.ahajournals.org>

DOI: 10.1161/CIRCGENETICS.115.001370

approach. This methodology is time intensive and involves a significant financial cost. As >100 known cardiac channelopathy- and cardiomyopathy-susceptibility genes have now been described, a comprehensive molecular evaluation seems out-of-reach for this standard practice. Therefore, the potential role of next-generation whole-exome sequencing (WES) to conduct a molecular autopsy has gained interest.

WES enables genetic interrogation of the coding region for an individual's estimated library of 20 000+ genes at a relatively reasonable research cost, \$1000 to \$2000 per sample.<sup>12</sup> This modality can provide a more comprehensive sudden death gene panel while allowing for future population-based epidemiological testing, potentially uncovering new disease-causing mutations or disease-predisposing single-nucleotide polymorphisms. However, the comprehensive nature of WES will lead invariably to identification of DNA variants which may or may not be involved in the clinical phenotype, termed variants of unknown/uncertain significance (VUS).<sup>13</sup> This has led the American College of Medical Genetics (ACMG) to release a policy statement regarding the need for higher standards in reporting because

of the risk of false-positive results burdening the consumer and healthcare system.<sup>14</sup> Herein, we set out to evaluate the role of WES in exertion-related SUDY cases where a previous 4 channelopathy gene molecular autopsy remained negative.

## Materials and Methods

### Medical Examiner/Coroner Referred Cases for Autopsy-Negative SUD

From September 1, 1998, through October 31, 2010, 32 unrelated autopsy-negative SUDY medical examiners/coroner cases who died during exertion between the ages of 1 and 19 years were referred to the Windland Smith Rice Sudden Death Genomics Laboratory at the Mayo Clinic in Rochester, Minnesota, for postmortem genetic testing (ie, molecular autopsy) after Mayo Clinic IRB approval and informed consent from the next of kin (Table 1).

All 32 cases had underwent previously a comprehensive mutational analysis via polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing of the major LQTS- (*KCNQ1*, *KCNH2*, and *SCN5A*) and CPVT- (*RYR2*) susceptibility genes.<sup>5</sup> A putative pathogenic mutation within these LQTS or CPVT genes was present in 11/32 (34%) cases. The remaining 21 cases remained genetically elusive.

**Table 1. Demographic Summary of the Exertion-Related SUDY Cohort**

	All Cases	Pathogenic Mutation-Positive Cases	Pathogenic Mutation-Negative Cases	<i>P</i> value
Number of Individuals	32	14	18	
Sex				
Male	20	8	12	0.72
Female	12	6	6	
Age at SUD				
Overall, mean±SD, y (range)	11.5±5.1 (2–19)	8.4±5.5 (2–17)	13.8±3.2 (6–19)	<b>0.002</b>
Females, mean±SD, y (range)	9.9±3.8 (5–17)	8.3±3.7 (5–15)	11.4±3.5 (6–17)	0.17
Males, mean±SD, y (range)	12.4±5.6 (2–19)	8.5±6.9 (2–17)	15.0±2.5 (11–19)	<b>0.01</b>
Reported ethnicity				
White	29	13	16	0.82
Black	2	1	1	
Hispanic	1	0	1	
Asian	0	0	0	
Unknown	0	0	0	
Personal history before SUD				
Positive, n (%)	10 (31)	6 (43)	4 (22)	0.27
Negative, n (%)	22 (69)	8 (57)	14 (78)	
Family history of cardiac events				
Positive, n (%)	5 (16)	1 (7)	4 (22)	0.35
Negative, n (%)	27 (84)	13 (93)	14 (78)	
Family history of SCD, n (%)	3 (9)	1 (7)	2 (11)	1.00
Personal or family history				
Seizures, n (%)	2 (6)	2 (14)	0	0.18
Syncope, n (%)	5 (16)	3 (21)	2 (11)	0.63

Values in bold represent *P* values considered statistically significant (defined as *P*<0.05). SCD indicates sudden cardiac death; SUD, sudden unexplained death; and SUDY, sudden unexplained death in the young.

## Whole-Exome Next-Generation DNA Sequencing

Three micrograms of genomic DNA isolated from an autopsy specimen (whole blood, blood spot card, or frozen tissue) from these 21 remaining SUDY cases was submitted to Mayo Clinic's Medical Genome Facility (Rochester, MN) for WES. Exome capture was completed with SureSelect XT Human All Exon V4 plus UTR Target Enrichment System (Agilent, Santa Clara, CA). Exome sequencing was performed using the Illumina HiSeq 2000 platform (San Diego, CA) and V3 reagents. Parameters included 71-Mb paired-end sequencing at 96% coverage with a read depth of 35x.

The sequence alignment and analysis was completed using the SNP & Variation Suite v8.3.4 (Golden Helix, Inc, Bozeman, MT, [www.goldenhelix.com](http://www.goldenhelix.com)). All variants were first filtered for a call quality score  $\geq 20$  and read depth  $\geq 10$ . Variants occurring in noncoding regions outside of the canonical splice sites or representing synonymous variants were excluded from further analysis. Only insertion/deletions and single nucleotide variants causing a missense, splice-site error, or nonsense substitution underwent gene-specific surveillance for all known channelopathy- and cardiomyopathy-susceptibility genes (N=100; Table I in the [Data Supplement](#)).

Only ultrarare variants with an allele frequency  $< 0.00005$  (1:20000 alleles) in the Exome Aggregation Consortium browser (n=60706 unrelated individuals) and with an ACMG consensus variant classification of pathogenic were considered to be causative and actionable clinically.<sup>14</sup> All variants designated as pathogenic were validated using Sanger DNA sequencing.

## Statistical Analysis

Descriptive statistics (means, percentages, etc) were used to summarize the data. Cohorts were compared using the Fischer exact test on SAS statistical software version 9.3 (SAS Institute, Cary, NC). *P* values  $< 0.05$  were considered significant.

## Results

### Cohort Description

The details regarding these 32 cases of exertion-related SUDY are summarized in Table 1. Briefly, there were 20 men and 12 women, the mean age at death was  $11 \pm 5$  years and ranged from 2 to 19 years, and 91% of the decedents were white. Of the 32 cases, the sudden death was the sentinel event in 22 (69%), whereas 10 (31%) experienced symptoms before their sudden death (5 with syncope, 2 with arrhythmias, 2 with seizures,

and 1 with palpitations). A family history of cardiac events was present in 5 of 32 cases (16%) with 3 cases notable for a family history of sudden cardiac death before 50 years of age.

### Whole-Exome Molecular Autopsy

On average, each SUDY case had  $9227 \pm 2098$  nonsynonymous variants. Of these variants,  $69 \pm 11$  localized to the 100 surveyed genes. In total, 12 ultrarare (allele frequency  $< 0.00005$  in Exome Aggregation Consortium) nonsynonymous variants were identified in 10 of 21 cases (47.6%) (2 cases had 2 variants, Table 2). However, only 3 variants (CALM2-F90L, CALM2-N98S, and PKP2-N634fs) were classified as pathogenic according to the strict variant interpretation guideline recommendations outlined by the ACMG and therefore were considered clinically actionable.<sup>14</sup> The remaining 9 ultrarare variants are still considered VUS. Comparison of victims with (n=7) and without (n=11) ultrarare VUS demonstrates no difference in clinical characteristics including age ( $14.3 \pm 4.6$  and  $13.5 \pm 2.3$  years;  $P=0.65$ ), sex (57% and 73% men;  $P=0.63$ ), race (86% and 91% white;  $P=1.0$ ), sudden death as the sentinel event (86% and 73%;  $P=1.0$ ), and family history of cardiac events (42% and 10%;  $P=0.25$ ).

Two of the decedents hosted mutations within the *CALM2* gene. *CALM2* is a member of the calmodulin gene family, which comprised 3 separate genes (*CALM1*, *CALM2*, and *CALM3*) that are unique at the nucleotide level and dispersed throughout the genome but all encode precisely the same calcium-binding protein. Mutations in all 3 calmodulin genes have been implicated previously in LQTS or CPVT.<sup>15–19</sup> The CALM2-N98S mutation was identified in a 2-year-old boy who died while dancing. This CALM2-N98S was seen previously as a sporadic mutation in a 12-year-old Japanese boy with syncope and QT prolongation.<sup>18</sup> The CALM2-F90L mutation was identified in a 5-year-old boy who died while playing. Although CALM2-F90L is novel, a CALM1-F90L mutation has been described previously.<sup>19</sup>

The third decedent is a 16-year-old boy who died suddenly while playing football. WES identified a frameshift deletion

**Table 2. Summary of Ultrarare Variants Identified via Whole-Exome Sequencing in the Exertion-Related SUDY Cohort**

Age, y	Sex	Gene	Nucleotide Change	Amino Acid Change	ACMG Designation	ExAC Minor Allele Frequency	Personal History	Family History
16	M	<i>ACTN2</i>	c.2356G>A	p.G786S	VUS	...	Negative	Negative
6	F	<i>ANKRD1</i>	c.722G>A	p.C241Y	VUS	0.00001649	Negative	Negative
5	M	<i>CALM2</i>	c.268T>C	p.F90L	Pathogenic	...	Negative	Negative
2	M	<i>CALM2</i>	c.293A>G	p.N98S	Pathogenic	...	Negative	Negative
18	M	<i>CASQ2</i> <i>DMD</i>	c.289A>G c.4025G>A	p.K97E p.R1342H	VUS VUS	0.00000841 0.00002304	Negative Negative	Negative Negative
12	F	<i>GATAD1</i>	c.157G>T	p.G53W	VUS	...	Negative	SCD
19	M	<i>MYBPC3</i> <i>DSG2</i>	c.2374T>C c.3040G>A	p.W792R p.V1014I	VUS VUS	... 0.00004972	Negative Negative	Negative Negative
12	M	<i>MYBPC3</i>	c.2500C>T	p.R834W	VUS	0.00001658	Syncope	Syncope
17	F	<i>MYL2</i>	c.430C>A	p.P144T	VUS	0.00000825	Negative	SCD
16	M	<i>PKP2</i>	c.1901delA	p.N634fs	Pathogenic	...	Negative	Negative

ACMG indicates American College of Medical Genetics; ExAC, Exome Aggregation Consortium; F, female; M, male; SCD, sudden cardiac death; SUDY, sudden unexplained death in the young; and VUS, variant of unknown significance.

**Table 3. Summary of Pathogenic Clinically Actionable Mutations Identified in the 32 Cases of Exertion-Related SUDY Cohort**

Age, y	Sex	Gene	Nucleotide Change	Amino Acid Change	Type of Exertion	Personal History	Family History
5	M	<i>CALM2</i>	c.268T>C*	p. F90L	Playing	Negative	Negative
2	M	<i>CALM2</i>	c.293A>G*	p. N98S	Dancing	Negative	Negative
8	F	<i>KCNQ1</i>	c. 935C>T	p. T312I	Playing	Negative	SCD
5	F	<i>KCNQ1</i>	c. 1750G>A	p. G584S	Playing	Syncope	Negative
16	M	<i>PKP2</i>	c.1901delA*	p. N634fs	Football	Negative	Negative
2	M	<i>RYR2</i>	c. 719A>G c. 12472A>C	p. H240R p. T4158P	Playing	Negative	Negative
17	M	<i>RYR2</i>	c. 1258C>T	p. R420W	Running	Syncope	Negative
4	M	<i>RYR2</i>	c. 6739C>T	p. S2246L	Playing	Negative	Negative
5	M	<i>RYR2</i>	c. 6737C>T	p. S2246L	Running	Negative	Negative
17	M	<i>RYR2</i>	c. 11636T>C	p. L3879P	Football	Syncope	Negative
9	F	<i>RYR2</i>	c. 11773C>G	p. Q3925E	Playing	Seizures	Negative
15	F	<i>RYR2</i>	c. 11876C>T	p. S3959L	Playing	Negative	Negative
5	F	<i>RYR2</i>	c. 13933T>A	p. W4645R	Playing	SVT	Negative
8	F	<i>RYR2</i>	c. 14803G>A	p. G4936R	Skating	Seizures	Negative

F indicates female; M, male; SCD, sudden cardiac death; and SVT, supraventricular tachycardia.

\*Patients with a pathological mutation previously unrecognized and identified by whole-exome sequencing.

mutation, p.N634fs, within the *PKP2* gene. *PKP2* encodes plakophilin-2, an essential armadillo-repeat protein in cardiac desmosomes, with mutations linked to arrhythmogenic right ventricular cardiomyopathy. Although this decedent's specific mutation is novel, pathogenicity is linked to previous data demonstrating insertion–deletion mutations, nonsense mutations, and missense mutations within *PKP2*, resulting in arrhythmogenic right ventricular cardiomyopathy.<sup>20</sup>


The surviving family members of all decedents with newly identified pathogenic mutations were contacted. The implications of the decedent's postmortem genetic test results were discussed, and the families were advised to undergo further cardiological evaluation that would include cascade genetic testing of the putative pathogenic mutation in a Clinical Laboratory Improvement Amendment certified facility. Notably, all 3 families have declined to pursue these recommendations thus far.

### Spectrum and Prevalence of Rare, Putative Pathogenic Mutations

Including our previous findings, 14 of 32 (44%) of these autopsy-negative SUDY cases with an exertion-associated sudden death have a putative pathogenic and clinically actionable mutation (9 cases with an *RYR2* mutation, 2 *KCNQ1*, 2 *CALM2*, and 1 *PKP2*; Table 3). One decedent hosted 2 *RYR2* mutations (RyR2-H240R and RyR2-T4158P).

An interesting age effect was noted when comparing mutation-positive versus mutation-negative cases. Mutation-positive cases (n=14; 8.4±5.5 years; range: 2–17 years) were significantly younger than mutation-negative cases (n=18; 13.8±3.2 years; range: 6–19 years;  $P=0.002$ ; Table 1). When these cases were subdivided further, there was a notable difference in age between mutation-positive male cases (n=8; 8.5±6.9 years) and mutation-negative male cases (n=12; 15.0±2.5 years;  $P=0.01$ ; Table 1). This

same relationship was not evident among mutation-positive female cases (n=6; 8.3±3.7 years) compared with mutation-negative female cases (n=6; 11.4±3.5;  $P=0.17$ ; Table 1). However, when stratified by age, the overall yield of pathogenic mutations was significantly higher among decedents ≤10 years (10/11, 91%) than cases aged >10 years (4/21,



**Figure 1.** Age effect on the molecular autopsy detection yield of pathogenic mutations: illustrated is a bar graph demonstrating the yield of pathogenic mutation detection for decedents aged 1 to 10 years in comparison to those aged 11 to 19 years. The number in parenthesis (n=x) represents the total number of cases. Each bar represents the percent yield for each. F indicates female; and M, male.

19%;  $P=0.0001$ ; Figure 1). There was no difference statistically between the mutation-positive and mutation-negative cases with regard to sex, ethnicity, personal history of symptoms before SUD, or family history of cardiac events including sudden cardiac death.

### Discussion

This is the largest single-center study demonstrating the use of a whole-exome molecular autopsy (WEMA) to identify pathogenic mutations in a population of exertionally related autopsy-negative SUDY victims. The mutation detection rate in this cohort improved from 34% with polymerase chain reaction, denaturing high-performance liquid chromatography, and direct DNA-sequencing analysis of only the 4 major channelopathy genes (*KCNQ1*, *KCNH2*, *SCN5A*, and *RYR2*) to 44% after expansion to a WEMA. The identification of these genetic alterations assists in providing closure and clarity for the family, while ensuring completion of proper evaluation of at-risk family members including predictive, mutation-specific genetic testing (cascade screening).

The population of exertion-related autopsy-negative SUDY cases was targeted in this study because of our previous observations of an elevated probability for an underlying identifiable pathogenic mutation associated with a channelopathy.<sup>5</sup> The rate of detection for a pathogenic mutation in exertion-related SUDY cases was greater for deceased children aged  $\leq 10$  years in comparison to those aged 11 to 19 years, especially among men. The same trend exists for women, but statistical significance was not ascertained, which was potentially limited because of sample size.

These results must be considered in the context of potential referral bias, with the study population potentially overestimating the true pathogenic mutation detection rate for this cohort and sample bias, with the overrepresentation of *RYR2* variants and the tendency for CPVT to present early in life. Even so, this information is of critical importance to the families of the decedents and pathologists, as the discussion to pursue a molecular autopsy is often limited because of financial constraints. Prioritization of cases may be necessary, and this study would suggest that victims with exertion-related SUDY before 10 years of age may have the highest pretest probability for a positive molecular autopsy.

We previously reported the first proof-of-principle case report on the role of a WEMA. A previously healthy 16-year-old girl with SUDY had a pathogenic *MYH7* mutation previously reported with hypertrophic cardiomyopathy and sudden death. Identification of this alteration allowed for appropriate genetic interrogation of her surviving at-risk family members.<sup>12</sup> This study confirms the use of WES for a comprehensive molecular autopsy with the identification of 3 pathogenic mutations in patients previously thought to be genotype-negative exertion-related SUDY cases. These 3 mutations were associated with 2 genes, *CALM2* and *PKP2*, previously implicated in SUD cases. The pathogenicity of c.293A>G in *CALM2* causing p.N98S and c.1901delA in *PKP2* causing p.N634fs has been established by previous investigations.<sup>18,20</sup> The designation of pathogenicity is based on the presence of PS1/PS2 and PVS1/PS3 criteria per the ACMG guidelines for each variant, respectively.<sup>14</sup>

The *CALM2* mutation, c.268T>C, causing p.F90L represents an interesting case. This nucleotide substitution in *CALM2* has not been reported. The calmodulin genes contain 8 highly conserved phenylalanine residues, including F90, encoding a helix-loop-helix calcium binding motif integral to signaling with target peptides.<sup>19,21,22</sup> Mutations within this signaling domain have displayed aberrant interaction with ryanodine receptor type 2 calmodulin-binding domain peptide at low calcium concentrations.<sup>23</sup> Decreased calmodulin-ryanodine receptor type 2 interaction would result in a dominant-negative effect, promoting an open ryanodine receptor type 2 configuration, as is seen in CPVT1-causing pathogenic mutations.<sup>17</sup> A *CALM1*-F90L mutation has been described previously as a familial disease-causing mutation in a Moroccan family with episodes of ventricular fibrillation within the first 2 decades of life and mild QT prolongation. This mutation was present in the mother and 4 affected siblings, although being absent in the unaffected father, unaffected sibling, and 500 Moroccan controls.<sup>19</sup> The designation of pathogenicity is therefore based on the presence of PS1/PS4 criteria per the ACMG guidelines.<sup>14</sup>

To date, 5 of the 100 interrogated channelopathic and cardiomyopathic genes have hosted “actionable” pathogenic mutations for more than one third of these exertion-related, autopsy-negative SUDY cases. The addition of the calmodulin and the plakophilin genes should be considered for molecular autopsies currently using direct DNA sequencing. The victim hosting the pathogenic *PKP2* variant in this study further supports that a standard forensic autopsy may fail to recognize subtle features of a cardiomyopathy or that sudden death may occur with subclinical disease. This supports the evaluation of cardiomyopathic genes in addition to channelopathy genes even in the setting of seemingly autopsy-negative SUD. With each addition of a targeted gene to the direct DNA-sequencing panel, the cost-effective nature of a WEMA becomes more apparent.

Although the idea of a WEMA is enticing, it is not without limitation. The technology is dependent on exome capture, sequencing quality, and read mapping with the potential for sequence artifact producing false-positive variants. Any putative mutation must therefore be validated via standard Sanger sequencing protocols. Furthermore, the comprehensive nature of WES will give rise to thousands of nonsynonymous genetic variants for each exome, many of which may be rare, predicted to be deleterious via various *in silico* tools, and even reside within biologically plausible genes. As evidenced in our cohort, half of the exertion-related SUDY cases have a VUS in one of the channelopathic or cardiomyopathic genes that remains stuck in genetic purgatory currently.<sup>13</sup> Strict criteria must be met before reporting pathogenicity to prevent undue burden on the decedent’s family and the healthcare system.

The multitude of sequence variants identified through high-throughput next-generation sequencing led the ACMG, the Association for Molecular Pathology, and the College of American Pathologists to publish standards required for the interpretation of sequence variants.<sup>14</sup> Criteria were developed for the classification of pathogenic and benign variants. The system is dynamic allowing for reclassification with the continued acquisition of knowledge. For example, confirmation of a *de novo* mutation in a patient with the

disease and no family history, functional studies supportive of a damaging effect on the gene, or prevalence studies documenting the presence of a mutation in the affected compared with controls may lead to reclassification of an otherwise ambiguous VUS to the designation of likely pathogenic or pathogenic. Uncertain significance is applied to variants that do not meet criteria for one of the classifications or when contradictory criteria between benign and pathogenic are present.

In our cohort, the currently ambiguous variants may one day be downgraded as benign or upgraded as a pathogenic, clinically actionable variant. Identification of a VUS result should not trigger familial testing of the decedent's surviving first-degree relatives who have a normal cardiac evaluation without careful counseling.<sup>24,25</sup> Specifically, the family must not conclude that a request for variant-specific testing of relatives implies that the root cause has been detected. Instead, the relatives must understand that an ambiguous variant has been found and that the VUS could be reclassified potentially, for example, if the VUS was determined to be a sporadic, de novo variant. Such a determination presumes correct maternity/paternity. Whether VUS testing of first-degree relatives is performed clinically or with informed consent on a research basis needs to be individualized. The key element that must be communicated in either setting is that the variant is being investigated further and that a conclusion of pathogenicity would be premature and incorrect. More work must be done. Until defined, these results produce a compendium of data allowing for ongoing evaluation in the search for new disease-associated mutations and multigenic models of disease. However, if appropriate restraint is not exercised, a VUS could be proclaimed erroneously and prematurely as the root cause. This could have disastrous consequences for the surviving family members. Arguably, the only thing worse than being unable to provide a family with a cogent explanation for their loved one's death is to proclaim that the root cause has been found and be wrong.

### Conclusion

Molecular screening in this clinical scenario, especially for the younger victim, is appropriate with a pathogenic mutation detection rate of 44%. Although WES may be a more cost-effective platform for obtaining genetic data than targeted gene-specific DNA sequencing, only 5 of the 100 so-called sudden death-associated genes have hosted actionable pathogenic mutations for more than one third of these exertion-related, autopsy-negative SUDY cases. WES results must be scrutinized with great caution because most variants will be stuck in genetic purgatory as a VUS. Future population-based, molecular epidemiology studies of SUDY will be needed to confirm whether the yield of actionable pathogenic mutations is truly greater in 1 to 10-year-old children with an exertion-related SUDY than in those aged 11 to 19 years.

### Sources of Funding

This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program, the Sheikh Zayed Saif Mohammed Al Nahyan Fund in Pediatric Cardiology Research, the Dr Scholl Fund, and the Hannah M. Wernke Memorial Fund. This

project was also supported in part by funding from Mayo Clinic's Center for Individualized Medicine.

### Disclosures

M.J. Ackerman is a consultant for Boston Scientific, Gilead Sciences, Medtronic, and St Jude Medical. M.J. Ackerman, D.J. Tester, and Mayo Clinic receive royalties from Transgenomic for their FAMILION-LQTS and FAMILION-CPVT genetic tests. However, none of these entities provided financial support for this study. The other authors report no conflicts.

### References

1. Liberthson RR. Sudden death from cardiac causes in children and young adults. *N Engl J Med*. 1996;334:1039–1044. doi: 10.1056/NEJM199604183341607.
2. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. *Circulation*. 2009;119:1085–1092. doi: 10.1161/CIRCULATIONAHA.108.804617.
3. Mellor G, Raju H, de Noronha SV, Papadakis M, Sharma S, Behr ER, et al. Clinical characteristics and circumstances of death in the sudden arrhythmic death syndrome. *Circ Arrhythm Electrophysiol*. 2014;7:1078–1083. doi: 10.1161/CIRCEP.114.001854.
4. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*. 2011;8:1308–1339. doi: 10.1016/j.hrthm.2011.05.020.
5. Tester DJ, Medeiros-Domingo A, Will ML, Haglund CM, Ackerman MJ. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. *Mayo Clin Proc*. 2012;87:524–539. doi: 10.1016/j.mayocp.2012.02.017.
6. Skinner JR, Crawford J, Smith W, Aitken A, Heaven D, Evans CA, et al; Cardiac Inherited Disease Group New Zealand. Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. *Heart Rhythm*. 2011;8:412–419. doi: 10.1016/j.hrthm.2010.11.016.
7. Kaufenstein S, Kiehne N, Jenewein T, Biel S, Kopp M, König R, et al. Genetic analysis of sudden unexplained death: a multidisciplinary approach. *Forensic Sci Int*. 2013;229:122–127. doi: 10.1016/j.forsciint.2013.03.050.
8. Kumar S, Peters S, Thompson T, Morgan N, Maccicco I, Trainer A, et al. Familial cardiological and targeted genetic evaluation: low yield in sudden unexplained death and high yield in unexplained cardiac arrest syndromes. *Heart Rhythm*. 2013;10:1653–1660. doi: 10.1016/j.hrthm.2013.08.022.
9. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. *J Am Coll Cardiol*. 2007;49:240–246. doi: 10.1016/j.jacc.2006.10.010.
10. Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. *Mayo Clin Proc*. 2004;79:1380–1384. doi: 10.4065/79.11.1380.
11. Winkel BG, Larsen MK, Berge KE, Leren TP, Nissen PH, Olesen MS, et al. The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases. *J Cardiovasc Electrophysiol*. 2012;23:1092–1098. doi: 10.1111/j.1540-8167.2012.02371.x.
12. Loporcaro CG, Tester DJ, Maleszewski JJ, Kruisselbrink T, Ackerman MJ. Confirmation of cause and manner of death via a comprehensive cardiac autopsy including whole exome next-generation sequencing. *Arch Pathol Lab Med*. 2014;138:1083–1089. doi: 10.5858/arpa.2013-0479-SA.
13. Ackerman MJ. Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. *Heart Rhythm*. 2015;12:2325–2331. doi: 10.1016/j.hrthm.2015.07.002.
14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–424. doi: 10.1038/gim.2015.30.

15. Reed GJ, Boczek NJ, Etheridge SP, Ackerman MJ. CALM3 mutation associated with long QT syndrome. *Heart Rhythm*. 2015;12:419–422. doi: 10.1016/j.hrthm.2014.10.035.
16. Crotti L, Johnson CN, Graf E, De Ferrari GM, Cuneo BF, Ovadia M, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. *Circulation*. 2013;127:1009–1017. doi: 10.1161/CIRCULATIONAHA.112.001216.
17. Nyegaard M, Overgaard MT, Søndergaard MT, Vranas M, Behr ER, Hildebrandt LL, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. *Am J Hum Genet*. 2012;91:703–712. doi: 10.1016/j.ajhg.2012.08.015.
18. Makita N, Yagihara N, Crotti L, Johnson CN, Beckmann BM, Roh MS, et al. Novel calmodulin mutations associated with congenital arrhythmia susceptibility. *Circ Cardiovasc Genet*. 2014;7:466–474. doi: 10.1161/CIRCGENETICS.113.000459.
19. Marsman RF, Barc J, Beekman L, Alders M, Dooijes D, van den Wijngaard A, et al. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. *J Am Coll Cardiol*. 2014;63:259–266. doi: 10.1016/j.jacc.2013.07.091.
20. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. *Nat Genet*. 2004;36:1162–1164. doi: 10.1038/ng1461.
21. Ohya Y, Botstein D. Diverse essential functions revealed by complementing yeast calmodulin mutants. *Science*. 1994;263:963–966.
22. Okano H, Cyert MS, Ohya Y. Importance of phenylalanine residues of yeast calmodulin for target binding and activation. *J Biol Chem*. 1998;273:26375–26382.
23. Yamaguchi N, Xu L, Pasek DA, Evans KE, Meissner G. Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release channel (ryanodine receptor). *J Biol Chem*. 2003;278:23480–23486. doi: 10.1074/jbc.M301125200.
24. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*. 2013;10:1932–1963. doi: 10.1016/j.hrthm.2013.05.014.
25. Wong LC, Roses-Noguer F, Till JA, Behr ER. Cardiac evaluation of pediatric relatives in sudden arrhythmic death syndrome: a 2-center experience. *Circ Arrhythm Electrophysiol*. 2014;7:800–806. doi: 10.1161/CIRCEP.114.001818.

### CLINICAL PERSPECTIVE

The use of whole-exome sequencing for a comprehensive molecular autopsy after direct DNA testing of the 4 major channelopathy-associated genes (*KCNQ1*, *KCNH2*, *SCN5A*, and *RYR2*) improved the yield of identifying a pathogenic mutation in the young patient with exertion-related sudden unexplained death. Prioritization of cases for a comprehensive molecular autopsy may be necessary, and when stratified by age, the overall yield of pathogenic mutations was higher among decedents aged 1 to 10 years, than those aged 11 to 19 years. In this setting of exertional sudden death in the young, the sudden death-causing pathogenic mutation (ie, smoking gun) was found in >40% of the cases enabling powerful closure for the family and clarity with respect to cascade screening of the decedent's relatives. In contrast to closure and clarity, the whole-exome molecular autopsy can cause great confusion also. Ultrarare variants of unknown significance in a plethora of genes were identified in one third of cases after a whole-exome molecular autopsy. Although such variants may one day be upgraded to pathogenic or downgraded to benign, we must refrain from assuming that a variant of unknown significance is actionable clinically and from proclaiming prematurely and erroneously that it (the variant) is the root cause.

## Whole-Exome Molecular Autopsy After Exertion-Related Sudden Unexplained Death in the Young

Jason H. Anderson, David J. Tester, Melissa L. Will and Michael J. Ackerman

*Circ Cardiovasc Genet.* 2016;9:259-265; originally published online April 25, 2016;  
doi: 10.1161/CIRCGENETICS.115.001370

*Circulation: Cardiovascular Genetics* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2016 American Heart Association, Inc. All rights reserved.  
Print ISSN: 1942-325X. Online ISSN: 1942-3268

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circgenetics.ahajournals.org/content/9/3/259>

Data Supplement (unedited) at:

<http://circgenetics.ahajournals.org/content/suppl/2016/04/25/CIRCGENETICS.115.001370.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Cardiovascular Genetics* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation: Cardiovascular Genetics* is online at:  
<http://circgenetics.ahajournals.org/subscriptions/>



**SUPPLEMENTAL MATERIAL**

**Supplemental Table 1. List of the 100 Potential Sudden Death-Associated Genes Analyzed in this Study**

<b>Number</b>	<b>Gene</b>	<b>Protein</b>	<b>Disease Association</b>
1	<i>ABCC9</i>	ATP-binding cassette, sub-family C (CFTR/MRP), member 9	DCM
2	<i>ACTC1</i>	actin, alpha, cardiac muscle 1	HCM, DCM
3	<i>ACTN2</i>	actinin, alpha 2	HCM, DCM
4	<i>AKAP9</i>	A kinase (PRKA) anchor protein (yotiao) 9	LQTS
5	<i>ANK2</i>	ankyrin 2	LQTS
6	<i>ANKRD1</i>	ankyrin repeat domain 1 (cardiac muscle)	HCM, DCM
7	<i>BAG3</i>	Bcl2-associated athanogene 3	DCM
8	<i>CACNA1C</i>	calcium channel, voltage-dependent, L type, alpha 1C subunit	BrS, LQTS
9	<i>CACNA2D1</i>	calcium channel, voltage-dependent, alpha 2/delta subunit 1	BrS
10	<i>CACNB2</i>	calcium channel, voltage-dependent, beta 2 subunit	BrS
11	<i>CALM1</i>	calmodulin 1	LQTS, CPVT
12	<i>CALM2</i>	calmodulin 2	LQTS
13	<i>CALM3</i>	calmodulin 3	LQTS
14	<i>CALR3</i>	calreticulin 3	HCM
15	<i>CASQ2</i>	calsequestrin 2 (cardiac muscle)	CPVT
16	<i>CAV3</i>	caveolin 3	LQTS
17	<i>CRYAB</i>	crystallin, alpha B	DCM
18	<i>CSRP3</i>	cysteine and glycine-rich protein 3 (cardiac LIM protein)	HCM, DCM
19	<i>CTF1</i>	cardiotrophin 1	DCM
20	<i>DES</i>	desmin	DCM
21	<i>DMD</i>	dystrophin, muscular dystrophy	DCM
22	<i>DSC2</i>	desmocollin 2	ACM
23	<i>DSG2</i>	desmoglein 2	ACM
24	<i>DSP</i>	desmoplakin	ACM
25	<i>EMD</i>	emerin (Emery-Dreifuss muscular dystrophy)	DCM
26	<i>EYA4</i>	eyes absent homolog 4 (Drosophila)	DCM
27	<i>FCMD</i>	fukuyama type congenital muscular dystrophy (fukutin)1	DCM
28	<i>FHL2</i>	four and a half LIM domains 2	DCM

29	<i>FXN</i>	frataxin	HCM
30	<i>GATA4</i>	GATA-binding protein 4	HCM
31	<i>GATAD1</i>	GATA zinc finger domain containing 1	DCM
32	<i>GLA</i>	galactosidase, alpha	HCM
33	<i>GPD1L</i>	glycerol-3-phosphate dehydrogenase 1-like	BrS
34	<i>HCN4</i>	hyperpolarization activated cyclic nucleotide-gated potassium channel 4	BrS
35	<i>ILK</i>	integrin-linked kinase	DCM
36	<i>JAG1</i>	jagged 1	HCM
37	<i>JPH2</i>	junctionophilin 2	HCM
38	<i>JUP</i>	junction plakoglobin	ARVC
39	<i>KCNA1</i>	potassium voltage-gated channel, shaker-related subfamily, member 1	SUDEP
40	<i>KCND3</i>	potassium voltage gated channel, Shal-related family, member 3	BrS
41	<i>KCNE1</i>	potassium voltage-gated channel, Isk-related family, member 1	LQTS
42	<i>KCNE2</i>	potassium voltage-gated channel, Isk-related family, member 2	LQTS
43	<i>KCNE3</i>	potassium voltage-gated channel, Isk-related family, member 3	BrS
44	<i>KCNH2</i>	potassium voltage-gated channel, subfamily H (eag-related), member 2	LQTS
45	<i>KCNJ2</i>	potassium inwardly-rectifying channel, subfamily J, member 2	LQTS
46	<i>KCNJ5</i>	potassium inwardly-rectifying channel, subfamily J, member 5	LQTS
47	<i>KCNJ8</i>	potassium inwardly-rectifying channel, subfamily J, member 8	BrS
48	<i>KCNQ1</i>	potassium voltage-gated channel, KQT-like subfamily, member 1	LQTS
49	<i>LAMA4</i>	laminin, alpha 4	DCM
50	<i>LAMP2</i>	lysosome-associated membrane glycoprotein 2	HCM
51	<i>LBD3</i>	LIM binding domain 3 (ZASP)	HCM, DCM
52	<i>LDB3</i>	LIM binding domain 3 (ZASP)	HCM, DCM
53	<i>LMNA</i>	lamin A/C	DCM
54	<i>MYBPC3</i>	myosin binding protein C, cardiac	HCM, DCM
55	<i>MYH6</i>	myosin, heavy chain 6, cardiac muscle, alpha	HCM, DCM
56	<i>MYH7</i>	myosin, heavy chain 7, cardiac muscle, beta	HCM, DCM
57	<i>MYL2</i>	myosin, light chain 2, regulatory,	HCM

		cardiac, slow	
58	<i>MYL3</i>	myosin, light chain 3, alkali; ventricular, skeletal, slow	HCM
59	<i>MYLK2</i>	myosin light chain kinase 2	HCM
60	<i>MYOM1</i>	myomesin 1, 185kDa	HCM
61	<i>MYOZ2</i>	myozenin 2	HCM
62	<i>MYPN</i>	myopalladin	HCM, DCM
63	<i>NEBL</i>	nebulette	DCM
64	<i>NEXN</i>	nexilin (F actin binding protein)	HCM, DCM
65	<i>NKX2.5</i>	NK2 transcription factor related 5	HCM
66	<i>PDLIM3</i>	PDZ and LIM domain 3	DCM
67	<i>PKP2</i>	plakophilin 2	ARVC
68	<i>PLN</i>	phospholamban	HCM, DCM
69	<i>PRKAG2</i>	protein kinase, AMP-activated, gamma 2 non-catalytic subunit	HCM
70	<i>PSEN1</i>	presenilin 1	DCM
71	<i>PSEN2</i>	presenilin 2	DCM
72	<i>PTPN11</i>	protein tyrosine phosphatase, non-receptor type 11	HCM
73	<i>RAF1</i>	v-raf-1 murine leukemia viral oncogene homolog 1	HCM
74	<i>RANGRF</i>	RAN guanine nucleotide release factor	BrS
75	<i>RBM20</i>	RNA binding motif protein 20	DCM
76	<i>RYR2</i>	ryanodine receptor 2 (cardiac)	CPVT, ARVC
77	<i>SCN1A</i>	sodium channel, voltage-gated, type I, alpha subunit	SUDEP
78	<i>SCN1B</i>	sodium channel, voltage-gated, type I, beta	BrS
79	<i>SCN3B</i>	sodium channel, voltage-gated, type III, beta	BrS
80	<i>SCN4B</i>	sodium channel, voltage-gated, type IV, beta	LQTS
81	<i>SCN5A</i>	sodium channel, voltage-gated, type V, alpha	LQTS, BrS, DCM
82	<i>SCN8A</i>	sodium channel, voltage gated, type VIII, alpha subunit	SUDEP
83	<i>SGCD</i>	sarcoglycan, delta (dystrophin-associated glycoprotein)	DCM
84	<i>SNTA1</i>	syntrophin, alpha 1	LQTS
85	<i>TAZ</i>	tafazzin	DCM, FAOD
86	<i>TBX1</i>	T-box 1	HCM
87	<i>TBX5</i>	T-box 5	HCM
88	<i>TCAP</i>	titin-cap (telethonin)	HCM, DCM

89	<i>TGFB3</i>	transforming growth factor, beta 3	ARVC
90	<i>TMEM43</i>	transmembrane protein 43	ARVC
91	<i>TMPO</i>	thymopoietin	DCM
92	<i>TNNC1</i>	troponin C type 1	HCM, DCM
93	<i>TNNI3</i>	troponin I type 3 (cardiac)	HCM, DCM
94	<i>TNNT2</i>	troponin T type 2 (cardiac)	HCM, DCM
95	<i>TPM1</i>	tropomyosin 1 (alpha)	HCM, DCM
96	<i>TRDN</i>	triadin	CPVT
97	<i>TTN</i>	titin	HCM, DCM
98	<i>TTR</i>	transthyretin	HCM, DCM
99	<i>TXNRD2</i>	thioredoxin reductase 2	DCM
100	<i>VCL</i>	vinculin	HCM, DCM

Genes listed alphabetically. Channelopathies: Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Long QT syndrome (LQTS).

Cardiomyopathies: arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM).